Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Vaccine ; 33 Suppl 3: C62-7, 2015 Jun 19.
Artigo em Inglês | MEDLINE | ID: mdl-25937612

RESUMO

The World Health Organization (WHO) in 2008 recommended the use of currently licensed typhoid vaccines using a high risk or targeted approach. The epidemiology of disease and the vaccine characteristics make school-based vaccination most feasible in reducing typhoid disease burden in many settings. To assess feasibility of school-based typhoid vaccination, two districts in Kathmandu, Nepal and two towns in Karachi, Pakistan were selected for pilot program. Vaccination campaigns were conducted through the departments of health and in partnerships with not-for-profit organizations. In total 257,015 doses of Vi polysaccharide vaccine were given to students in grades 1-10 of participating schools. The vaccination coverage ranged from 39 percent (38,389/99,503) in Gulshan town in Karachi, to 81 percent (62,615/77,341) in Bhaktapur in Kathmandu valley. No serious adverse event was reported post vaccination. The coverage increased for vaccination of the second district in Pakistan as well as in Nepal. There was an initial concern of vaccine safety. However, as the campaign progressed, parents were more comfortable with vaccinating their children in schools. Supported and conducted by departments of health in Pakistan and Nepal, a school-based typhoid vaccination was found to be safe and feasible.


Assuntos
Febre Tifoide/prevenção & controle , Vacinas Tíficas-Paratíficas/administração & dosagem , Criança , Humanos , Nepal/epidemiologia , Paquistão/epidemiologia , Pais/psicologia , Segurança do Paciente , Projetos Piloto , Serviços de Saúde Escolar , Estudantes , Febre Tifoide/epidemiologia , Vacinas Tíficas-Paratíficas/imunologia , Vacinação , Adulto Jovem
2.
PLoS One ; 9(1): e77974, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24400067

RESUMO

Salmonella Typhi, first isolated in 1884, results in infection of the intestines and can end in death and disability. Due to serious adverse events post vaccination, whole cell killed vaccines have been replaced with new generation vaccines. The efficacy of Vi polysaccharide (ViPS) vaccine, a new generation, single-dose intramuscular typhoid vaccine was assessed in Nepal in 1987. However, despite the availability of ViPS vaccine for more than 25 years, Nepal has one of the highest incidence of typhoid fever. Therefore we collected information from hospitals in the Kathmandu Valley from over the past five years. There were 9901 enteric fever cases between January 2008 and July 2012. 1,881 of these were confirmed typhoid cases from five hospitals in the Kathmandu district. Approximately 70% of the cases involved children under 15 years old. 1281 cases were confirmed as S. Paratyphi. Vaccines should be prioritized for control of typhoid in conjunction with improved water and sanitation conditions in Nepal and in endemic countries of Asia and Africa.


Assuntos
Salmonella typhi/imunologia , Febre Tifoide/prevenção & controle , Vacinas Tíficas-Paratíficas/imunologia , História do Século XX , História do Século XXI , Humanos , Nepal/epidemiologia , Vigilância da População , Prevalência , Estudos Retrospectivos , Febre Tifoide/história , Vacinas Tíficas-Paratíficas/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA